18.96
-2.22%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zylox-Tonbridge Medical Technology Co
Its shares trade on HKEX under the ticker 2190.HK. It has been listed since 5 July 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.06bn and net income of CN¥244.4m. At that date it held total assets of CN¥3.58bn and shareholders' equity of CN¥3.23bn.
Zylox-Tonbridge Medical Technology Co., Ltd. engages in the production and sales of neurovascular and peripheral-vascular interventional surgical devices. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-07-05. The firm's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB). The firm's products are sold to domestic and foreign markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 5 Jul 2021
- Employees
- 707
- Website
- zyloxtb.com ↗
Leadership
Pay as last reported
- Dr. Jonathon ZhaoExecutive Chairman of the Board, Chief Executive Officer, Founder, since 2012CN¥16.2m
- Mr. Quanwei YuanChief Financial Officer, Joint Company Secretary
- Dr. Zheng LiSenior Vice President, Executive Director, since 2019CN¥8.4m
- Mr. Yang XieSenior Vice President, Executive Director, since 2018CN¥6.2m
- Dr. Ning PanSenior Vice President
- Mr. Kai Cheong CheungJoint Company Secretary
- Mr. Dongfang LiNon-Executive Director
- Dr. Dasong WangNon-Executive Director
- Mr. Hui WangNon-Executive Director
- Dr. Jian JiNon-Executive Independent DirectorCN¥167,000
- Mr. Hongze LiangNon-Executive Independent DirectorCN¥167,000
- Ms. Yun QiuNon-Executive Independent DirectorCN¥167,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zylox-Tonbridge Medical Technology Co Ltd employs 707 full-time employees in Hangzhou, China.
- Thrombite CRD and Ultrafree DCB are key products for neurovascular and peripheral-vascular interventions.
- The company's domestic and foreign market sales demonstrate strong global reach.
Weaknesses
- The company's IPO date of 5 July 2021 indicates a relatively young market presence.
- Limited product range beyond neurovascular and peripheral-vascular devices.
- Hangzhou headquarters may limit access to international markets compared to global hubs.
Opportunities
- Expanding into new markets for neurovascular and peripheral-vascular devices globally.
- Increasing demand for advanced medical devices in the Health Care sector.
- Growing international market for Thrombite CRD and Ultrafree DCB products.
Threats
- Competition from established medical device manufacturers in China.
- Regulatory challenges in foreign markets for medical device sales.
- Economic downturns affecting healthcare spending in global markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.